Cost Saving Brands. Our range of cost saving brands has helped CCGs achieve over ￡30m in savings across multiple therapeutic classes.
Using a Category C Strategy, offering guaranteed sustainable supply and cost saving, over 100 CCG’s are working with Aspire to deliver these benefits to patients and the NHS.
For further information on the range click here
For individual product websites please click a brand logo:
In 2017 Aspire launched a range of innovative, preservative free, multi dose eye drops under the ‘ey’ umbrella brand.
These products were developed in direct response to ophthalmologists’ requests.
Our ability to combine new device technology with established molecules, has created intellectual property and a thoughtfully designed, patient focussed, range of medicines that provide significant saving potential.
For further information on the ‘ey’ range click here
Our Glaucoma Treatment Money Saving Strategy
In 2010, Aspire launched iAluRil?, the first combination GAG replacement therapy, for cystitis of various aetiologies.
Since launch, we have continued to adapt and improve the product; initially through the addition of a pre-filled syringe, making administration easier for the clinician and latterly for the patient, through the launch of a new adapter, making iAluRil the first non-invasive, catheterisation free, bladder instillation in the UK.
Our sales team continue to drive impressive growth of the product, through direct promotion to hospital-based urologists and their clinical staff.
For further information on iAluRil click here
Lecicarbon? A Suppository is suitable for adults and children over 12 years of age.
Lecicarbon? C Suppository is suitable for children under 12 years of age.
Fits into current practice for treating community acquired pneumonia (CAP)
Low potential for drug interactions
Better infusion site tolerability than clarithromycin
For further information on Zedbac click here